Clinical trial · Interventional
S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer
Phase II Trial of Concurrent Cisplatin/Docetaxel and Radiotherapy Followed by Consolidation Docetaxel in Stage IIIB Non-Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This study was closed early due to poor accrual.
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have stage IIIB non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- chemo/RT followed by consolidation chemo
- description
- cisplatin docetaxel radiation therapy
- interventionNames
- Drug: cisplatin
- Drug: docetaxel
- Radiation: radiation therapy
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed stage IIIB non-small cell lung cancer * Adenocarcinoma * Large cell carcinoma * Squamous cell carcinoma * Pathologically or radiographically documented positive N3 nodes * No positive supraclavicular or scalene lymph nodes with disease extending into the cervical region OR * T4 tumor invading any of the following: * Mediastinum * Heart * Great vessels * Trachea * Esophagus * Vertebral body * Carina * No brain, contralateral chest, liver, or adrenal metastases * No more than 1 parenchymal lesion * No malignant pleural effusions unless they are only visible on CT scan or deemed too small to tap * No pericardial effusions * Measurable disease PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Zubrod 0-2 Life expectancy: * Not specified Hematopoietic: * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Not specified Renal: * Creatinine clearance at least 50 mL/min Pulmonary: * One of the following: * FEV1 at least 2.0 L * Predicted FEV1 of contralateral lung greater than 800 mL * Predicted post-treatment FEV1 at least 1.0 L Other: * No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * No concurrent growth factors during induction chemoradiotherapy Chemotherapy: * No prior chemotherapy for lung cancer Endocrine therapy: * Not specified Radiotherapy: * No prior radiotherapy for lung cancer Surgery: * No prior surgical resection of lung cancer * Prior exploratory thoracotomy, mediastinoscopy, excisional biopsy, or similar surgery for determining diagnosis, stage, or potential resectability allowed
References
Publications (0)
Data not yet available